What is Lifesci Capital's Forecast for MLTX Q3 Earnings?

Key Points

• Lifesci Capital has downgraded its Q3 2025 earnings per share estimate for MoonLake Immunotherapeutics to ($0.91), down from a previous forecast of ($0.70).
• The company's recent earnings report showed ($0.87) EPS, missing analysts' consensus estimates of ($0.73) by ($0.14).
• Despite the negative forecast, MoonLake Immunotherapeutics maintains a consensus rating of "Moderate Buy" among analysts, with an average target price of $74.43.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Free Report) - Research analysts at Lifesci Capital cut their Q3 2025 earnings per share estimates for MoonLake Immunotherapeutics in a research report issued to clients and investors on Tuesday, August 5th. Lifesci Capital analyst R. Katkhuda now expects that the company will earn ($0.91) per share for the quarter, down from their prior forecast of ($0.70). The consensus estimate for MoonLake Immunotherapeutics' current full-year earnings is ($1.79) per share. Lifesci Capital also issued estimates for MoonLake Immunotherapeutics' Q4 2025 earnings at ($0.94) EPS.

MoonLake Immunotherapeutics (NASDAQ:MLTX - Get Free Report) last issued its earnings results on Tuesday, August 5th. The company reported ($0.87) earnings per share for the quarter, missing analysts' consensus estimates of ($0.73) by ($0.14). During the same period in the prior year, the business earned ($0.39) earnings per share.

A number of other brokerages have also weighed in on MLTX. Wolfe Research raised MoonLake Immunotherapeutics from a "peer perform" rating to an "outperform" rating and set a $61.00 target price on the stock in a research report on Monday, May 19th. Needham & Company LLC reiterated a "buy" rating and set a $66.00 price target on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Royal Bank Of Canada reiterated an "outperform" rating and set a $67.00 price target on shares of MoonLake Immunotherapeutics in a report on Tuesday, June 3rd. Wedbush reiterated an "outperform" rating and set a $80.00 price target (up previously from $78.00) on shares of MoonLake Immunotherapeutics in a report on Tuesday, May 13th. Finally, Redburn Atlantic upgraded MoonLake Immunotherapeutics to a "hold" rating in a report on Monday, July 28th. Two analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat, MoonLake Immunotherapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $74.43.

MoonLake Immunotherapeutics Stock Up 1.0%

Shares of NASDAQ:MLTX traded up $0.51 during trading on Friday, reaching $52.40. 274,326 shares of the stock were exchanged, compared to its average volume of 518,204. The company has a debt-to-equity ratio of 0.21, a current ratio of 16.65 and a quick ratio of 21.11. MoonLake Immunotherapeutics has a 1-year low of $31.42 and a 1-year high of $58.26. The stock has a fifty day moving average of $48.87 and a two-hundred day moving average of $43.14. The firm has a market cap of $3.35 billion, a price-to-earnings ratio of -18.85 and a beta of 1.27.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the company. Deutsche Bank AG lifted its holdings in MoonLake Immunotherapeutics by 59.8% during the 4th quarter. Deutsche Bank AG now owns 903 shares of the company's stock worth $49,000 after purchasing an additional 338 shares in the last quarter. Geode Capital Management LLC lifted its holdings in MoonLake Immunotherapeutics by 0.9% during the 4th quarter. Geode Capital Management LLC now owns 58,950 shares of the company's stock worth $3,192,000 after purchasing an additional 540 shares in the last quarter. PNC Financial Services Group Inc. lifted its holdings in MoonLake Immunotherapeutics by 8.2% during the 1st quarter. PNC Financial Services Group Inc. now owns 9,200 shares of the company's stock worth $359,000 after purchasing an additional 700 shares in the last quarter. MPM Bioimpact LLC lifted its holdings in MoonLake Immunotherapeutics by 0.3% during the 1st quarter. MPM Bioimpact LLC now owns 316,049 shares of the company's stock worth $12,348,000 after purchasing an additional 819 shares in the last quarter. Finally, US Bancorp DE lifted its holdings in MoonLake Immunotherapeutics by 114.4% during the 1st quarter. US Bancorp DE now owns 2,208 shares of the company's stock worth $86,000 after purchasing an additional 1,178 shares in the last quarter. Institutional investors own 93.85% of the company's stock.

About MoonLake Immunotherapeutics

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.